ASRS President Reflects on a Year of Change
-
By
-
Geoffrey G. Emerson, MD, PhD, FASRS
-
July 15, 2026
-
3 min
By
Geoffrey G. Emerson, MD, PhD, FASRS
July 15, 2026
Phase 1 nonrandomized trial reported no drug-related serious adverse events, but efficacy remains unproven
by Kerri Miller
May 7, 2026
US claims data showed rising prevalence of diabetic retinal disease in type 1 and type 2 diabetes, while incidence declined in type 1 diabetes and moved closer to type 2 rates by 2022.
April 15, 2026
At OIS Retina, Eric Schlumpf discussed the company’s collagen mimetic peptide platform for retinitis pigmentosa, now in preclinical development.
July 15, 2026